Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer In Postmenopausal Hormone Receptors Positive Patients Following Of 2-3 Years of Initial Adjuvant Tamoxifen Therapy

NCT01121549 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01121549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01121549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer In Postmenopausal Hormone Receptors Positive Patients Following Of 2-3 Years of Initial Adjuvant Tamoxifen Therapy
Lead sponsor
Pfizer
Phase
Observational
Overall status
Terminated
Start date
February 28, 2010
Completion date
December 31, 2012
Enrollment
378 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

invasive early breast cancer